METHOD FOR THE TREATMENT OF CROHN'S DISEASE WITH ANTI-IL23-SPECIFIC ANTIBODIES
Patent Information
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- JANSSEN BIOTECH INC
- Filing Date
- 2022-10-27
- Publication Date
- 2026-05-06
AI Technical Summary
Current treatments for moderately to severely active Crohn's disease, including biologic agents like TNF antagonists and IL-12/23 inhibitors, fail to achieve and maintain long-term remission in a significant proportion of patients, highlighting an unmet need for novel therapies with different mechanisms of action.
Administering guselkumab, an IL-23-specific antibody, through a specific dosing regimen of initial and follow-up subcutaneous doses to target IL-23, thereby modulating the immune response and achieving clinical remission in Crohn's disease.
The regimen significantly improves clinical endpoints such as Crohn's Disease Activity Index, patient-reported outcomes, and endoscopic assessments, with reduced adverse events, demonstrating a novel and effective treatment approach.